4.4 Article

Landscape of Microsatellite Instability Across 39 Cancer Types

期刊

JCO PRECISION ONCOLOGY
卷 1, 期 -, 页码 -

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/PO.17.00073

关键词

-

类别

资金

  1. American Cancer Society [MRSG-12-194-01-TBG]
  2. Prostate Cancer Foundation Young Investigator Award
  3. National Human Genome Research Institute [UM1HG006508]
  4. National Cancer Institute [UH2CA202971]
  5. American Lung Association
  6. Pelotonia
  7. FORE Cancer Research
  8. T32 Oncology Training Grant [5T32-CA009338]
  9. Helene Fuld Health Trust Nursing Scholarship
  10. National Human Genome Research Institute Large-Scale Sequencing Program Grant [U54-HG003067]

向作者/读者索取更多资源

Purpose Microsatellite instability (MSI) is a pattern of hypermutation that occurs at genomic microsatellites and is caused by defects in the mismatch repair system. Mismatch repair deficiency that leads to MSI has been well described in several types of human cancer, most frequently in colorectal, endometrial, and gastric adenocarcinomas. MSI is known to be both predictive and prognostic, especially in colorectal cancer; however, current clinical guidelines only recommend MSI testing for colorectal and endometrial cancers. Therefore, less is known about the prevalence and extent of MSI among other types of cancer. Methods Using our recently published MSI-calling software, MANTIS, we analyzed whole-exome data from 11,139 tumor-normal pairs from The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments projects and external data sources across 39 cancer types. Within a subset of these cancer types, we assessed mutation burden, mutational signatures, and somatic variants associated with MSI. Results We identified MSI in 3.8% of all cancers assessed-present in 27 of tumor types-most notably adrenocortical carcinoma (ACC), cervical cancer (CESC), and mesothelioma, in which MSI has not yet been well described. In addition, MSI-high ACC and CESC tumors were observed to have a higher average mutational burden than microsatellite-stable ACC and CESC tumors. Conclusion We provide evidence of as-yet-unappreciated MSI in several types of cancer. These findings support an expanded role for clinical MSI testing across multiple cancer types as patients with MSI-positive tumors are predicted to benefit from novel immunotherapies in clinical trials. (C) 2017 by American Society of Clinical Oncology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据